Literature DB >> 23596290

Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric units.

Robin Löving1, Mathilda Sjöberg, Shang-Rung Wu, James M Binley, Henrik Garoff.   

Abstract

The HIV-1 spike is composed of three protomeric units, each containing a peripheral gp120 and a transmembrane gp41 subunit. Binding to the CD4 and the chemokine receptors triggers them to mediate virus entry into cells by membrane fusion. The spikes also represent the major target for neutralizing antibodies (Abs) against the virus. We have studied how two related broadly neutralizing Abs, PG9 and PG16, react with the spike. Unexpectedly, this also suggested how the functions of the individual protomers in the spike depend on each other. The Abs have been shown to bind the V1/V2 loops of gp120, located at the top of the spike. Using blue native-polyacrylamide gel electrophoresis (BN-PAGE), we show that only single Abs or antigen-binding fragments could bind to the spikes of HIV-1 virus-like particles. Apparently, binding to one gp120 sterically interferes with binding to the other two subunits in the spike top. Despite this constraint, all of the protomers of the spike became resistant to CD4 binding and subsequent formation of the coreceptor binding site. These activities were measured by monitoring the sequential complex formation of the spike first with Abs and then with soluble 2d- or 4d-CD4 or with soluble CD4 and the CD4 inducible coreceptor binding site Ab 17b in BN-PAGE. The inhibition of the spike by single-Ab binding suggested that the activation reactions of the individual protomeric units are linked to each other in a coordinated activation process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596290      PMCID: PMC3676117          DOI: 10.1128/JVI.00530-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

2.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Capture of an early fusion-active conformation of HIV-1 gp41.

Authors:  R A Furuta; C T Wild; Y Weng; C D Weiss
Journal:  Nat Struct Biol       Date:  1998-04

4.  Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion.

Authors:  L G Abrahamyan; R M Markosyan; J P Moore; F S Cohen; G B Melikyan
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

9.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  12 in total

1.  Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.

Authors:  Tommy Tong; Keiko Osawa; James E Robinson; Ema T Crooks; James M Binley
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

2.  Sequential activation of the three protomers in the Moloney murine leukemia virus Env.

Authors:  Mathilda Sjöberg; Robin Löving; Birgitta Lindqvist; Henrik Garoff
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

Review 3.  HIV broadly neutralizing antibody targets.

Authors:  Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

4.  Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.

Authors:  Hillel Haim; Ignacio Salas; Kathleen McGee; Noah Eichelberger; Elizabeth Winter; Beatriz Pacheco; Joseph Sodroski
Journal:  Cell Host Microbe       Date:  2013-11-13       Impact factor: 21.023

5.  Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.

Authors:  M Asokan; R S Rudicell; M Louder; K McKee; S O'Dell; G Stewart-Jones; K Wang; L Xu; X Chen; M Choe; G Chuang; I S Georgiev; M G Joyce; T Kirys; S Ko; A Pegu; W Shi; J P Todd; Z Yang; R T Bailer; S Rao; P D Kwong; G J Nabel; J R Mascola
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

6.  Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.

Authors:  Ema T Crooks; Tommy Tong; Bimal Chakrabarti; Kristin Narayan; Ivelin S Georgiev; Sergey Menis; Xiaoxing Huang; Daniel Kulp; Keiko Osawa; Janelle Muranaka; Guillaume Stewart-Jones; Joanne Destefano; Sijy O'Dell; Celia LaBranche; James E Robinson; David C Montefiori; Krisha McKee; Sean X Du; Nicole Doria-Rose; Peter D Kwong; John R Mascola; Ping Zhu; William R Schief; Richard T Wyatt; Robert G Whalen; James M Binley
Journal:  PLoS Pathog       Date:  2015-05-29       Impact factor: 6.823

Review 7.  Structural insights on the role of antibodies in HIV-1 vaccine and therapy.

Authors:  Anthony P West; Louise Scharf; Johannes F Scheid; Florian Klein; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

8.  Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.

Authors:  Jeong Hyun Lee; Daniel P Leaman; Arthur S Kim; Alba Torrents de la Peña; Kwinten Sliepen; Anila Yasmeen; Ronald Derking; Alejandra Ramos; Steven W de Taeye; Gabriel Ozorowski; Florian Klein; Dennis R Burton; Michel C Nussenzweig; Pascal Poignard; John P Moore; Per Johan Klasse; Rogier W Sanders; Michael B Zwick; Ian A Wilson; Andrew B Ward
Journal:  Nat Commun       Date:  2015-09-25       Impact factor: 14.919

9.  Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization.

Authors:  Arthur S Kim; Daniel P Leaman; Michael B Zwick
Journal:  PLoS Pathog       Date:  2014-07-24       Impact factor: 6.823

10.  A saposin-lipoprotein nanoparticle system for membrane proteins.

Authors:  Jens Frauenfeld; Robin Löving; Jean-Paul Armache; Andreas F-P Sonnen; Fatma Guettou; Per Moberg; Lin Zhu; Caroline Jegerschöld; Ali Flayhan; John A G Briggs; Henrik Garoff; Christian Löw; Yifan Cheng; Pär Nordlund
Journal:  Nat Methods       Date:  2016-03-07       Impact factor: 28.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.